Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

NCT01327885 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01327885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 10, 2011
Completion date
August 10, 2016
Enrollment
452 (actual)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma